Media Center Wed, 31 May 2023 Pathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 Program for Upacicalcet in Patients Receiving Hemodialysis Wed, 12 Apr 2023 Launch Therapeutics Selects Medidata AI Intelligent Trials to Accelerate Clinical Trial Development Wed, 18 Jan 2023 Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies Mon, 15 Aug 2022 Launch Therapeutics partners with Opthea to advance OPT-302, a promising therapy for wet AMD Mon, 11 APRIL 2022 Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth
